Pharmaceuticals, Biotechnology and Life Sciences
Veidekke’s Danish subsidiary Hoffmann has been awarded a contract to build a new national research and treatment centre for particle therapy in Aarhus in Jutland.
Several individuals in German-speaking Switzerland are suspected of offences against the Therapeutic Products Act.
Pfizer Inc., the specialist in making contraceptive medicine, best known for making Viagra, has announced that its injectable contraceptive, Sayana Press (medroxyprogesterone acetate), is now available to women in the United Kingdom (UK) for administration by self-injection.
New clinical data and abstracts on Roche’s Esbriet (pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF) are being presented at the European Respiratory Society (ERS) congress in Amsterdam.
Bayer CropScience inaugurated its new European Oilseed Processing Center in Monheim at a ceremony attended by industry representatives, authorities, agricultural stakeholders and customers.
Allergan plc has updated its second-half 2015 continuing operations financial forecast. The forecast reflects adjustments for the upcoming expected discontinued operations
Eli Lilly has entered into a settlement agreement to resolve patent litigation with Sanofi regarding its insulin glargine product, Basaglar.
Phase II study of its Cyramza (ramucirumab) in combination with docetaxel met its primary endpoint, demonstrating a statistically significant increase in progression-free survival (PFS) for patients with locally advanced or metastatic urothelial carcinoma who failed prior platinum-based therapy.
Collagen Solutions plc, has announced that its subsidiary Collagen Solutions Inc. has signed a supply agreement with Turkish medical device company Yücel Medikal Ltd.
Novartis has announced results of a Phase III pivotal study showing Afinitor (everolimus) tablets reduced the risk of progression by 52% vs placebo in patients with advanced, progressive, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin.